Bosutinib Monohydrate Patent Expiration
Bosutinib Monohydrate is used for treating BCR-ABL positive leukemia resistant to imatinib, including patients with specific BCR-ABL mutations and various phases of CML. It was first introduced by Pf Prism Cv
Bosutinib Monohydrate Patents
Given below is the list of patents protecting Bosutinib Monohydrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bosulif |
US11103497 (Pediatric) | Treatment of imatinib resistant leukemia | Aug 28, 2034 | Pf Prism Cv |
| Bosulif | US11103497 | Treatment of imatinib resistant leukemia | Feb 28, 2034 | Pf Prism Cv |
| Bosulif |
US7767678 (Pediatric) | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same | May 23, 2027 | Pf Prism Cv |
| Bosulif | US7767678 | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same | Nov 23, 2026 | Pf Prism Cv |
| Bosulif |
US7417148 (Pediatric) | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | Jun 11, 2026 | Pf Prism Cv |
| Bosulif |
US7919625 (Pediatric) | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | Jun 11, 2026 | Pf Prism Cv |
| Bosulif | US7417148 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | Dec 11, 2025 | Pf Prism Cv |
| Bosulif | US7919625 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | Dec 11, 2025 | Pf Prism Cv |
| Bosulif |
USRE42376 (Pediatric) | Substituted 3-cyanoquinolines |
Oct 13, 2024
(Expired) | Pf Prism Cv |
| Bosulif | USRE42376 | Substituted 3-cyanoquinolines |
Apr 13, 2024
(Expired) | Pf Prism Cv |
| Bosulif | US6002008 | Substituted 3-cyano quinolines |
Mar 27, 2018
(Expired) | Pf Prism Cv |
| Bosulif | US6002008 | Substituted 3-cyano quinolines |
Mar 27, 2018
(Expired) | Pf Prism Cv |
Bosutinib Monohydrate's Family Patents
Explore Our Curated Drug Screens
Bosutinib Monohydrate Generic API Manufacturers
Several generic applications have been filed for Bosutinib Monohydrate.
Given below is the list of companies who have filed for Bosutinib Monohydrate generic, along with the locations of their manufacturing plants worldwide.
1. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Bosutinib Monohydrate. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet | Prescription | ORAL | AB | May 23, 2025 |
| EQ 500MG BASE | tablet | Prescription | ORAL | AB | May 23, 2025 |
Manufacturing Plant Locations New
Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||